Mr. Aguillard will be leading the commercialization efforts for the DermTech Melanoma Test.

Mark Aguillard is DermTech, Inc.’s chief commercial officer effective September 19, 2023. 

Mr. Aguillard will lead DermTech’s overall commercial strategy and execution.

Prior to joining is DermTech, Mr. Aguillard served as the chief commercial officer of Epic Sciences, where he led the development and launch of a novel liquid biopsy, DefineMBC, designed to personalize treatment for patients with metastatic breast cancer. Before that, he served in commercial leadership roles with Myriad Genetics, binx health, OmniSeq and Eli Lilly & Company directing sales, marketing, medical affairs, customer success and market access teams across oncology and women’s health. Mr. Aguillard received his Bachelor’s in Business Administration with a major in Finance from Texas Tech University.

“We are confident that his demonstrated success and wide breadth of commercial and payer access experience will serve us well during this transformational period as we focus on generating reimbursed tests to grow revenue,” says Bret Christensen, DermTech’s CEO, in a news release. “Mark’s leadership will be important as we strive to integrate the DermTech Melanoma Test (DMT) into the melanoma care pathway.”

Mr. Aguillard adds, “I’m excited to be leading the commercialization efforts for the DMT. Patient access is critical as we deploy our technology to evaluate suspicious pigmented lesions and potentially save lives. I’m impressed by DermTech’s accomplishments and I look forward to partnering with the team to accelerate revenue growth and scale the business to reach more patients.”